Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Two of Britain’s leading biomedical researchers, Professor Sir Ravinder Maini and Professor Sir Marc Feldmann, have been awarded the 2014 Canada Gairdner International Award.

Two of Britain’s leading biomedical researchers, Professor Sir Ravinder Maini and Professor Sir Marc Feldmann, have today been awarded the 2014 Canada Gairdner International Award for their research into anti-TNF (tumour necrosis factor) treatment, which, in significant part, was funded by Arthritis Research UK. The Canada Gairdner Award, recognised internationally as one of the top prizes for biomedical research, highlights and celebrates those scientists who have made groundbreaking medical discoveries that have had a profound effect on the understanding and awareness of human biology and disease. The pioneering research studies celebrated by the awards often lead to the diagnosis, treatment and cure of diseases.

In the mid-1980s Professor Sir Ravinder Maini and Professor Sir Marc Feldmann, then based at Arthritis Research UK’s Kennedy Institute of Rheumatology in west London, discovered which molecules in rheumatoid arthritis were driving the inflammation and destruction of joints, enabling them to develop a viable and effective treatment for rheumatoid arthritis. The research has had a major impact worldwide, providing new and effective treatment for resistant rheumatoid arthritis patients, which has benefitted millions of patients with severe disease.

Rheumatoid arthritis is a chronic inflammatory disease affecting the immune system. It affects around 400,000 people in the UK, and causes pain, stiffness and swelling in the joints. It can lead to chronic disability and reduced life expectancy. Previous treatment options left almost half of patients with symptoms of continuing disease, deterioration of physical function and progressive joint damage.

In a series of experiments using tissue taken from joints, Maini and Feldmann investigated the role of cytokines – protein messenger molecules which drive inflammation – and found that a number of pro-inflammatory cytokines were present in the inflamed joints. However they found that a single cytokine, TNF, was capable of driving the disease process. This led them to seek ways of proving this concept in patients, using a monoclonal antibody to block TNF.

The first clinical trial was performed in 1992 and revealed rapid and dramatic improvement of rheumatoid disease activity with anti-TNF therapy. The successful clinical trials in the UK, further claims for more exploratory trials within Europe and USA led to the development of three anti-TNF drugs – infliximab, etanercept and adalimumab. These drugs are effective in about 70% patients with severe disease, even those resistant to all previous treatment. Most importantly this new class of drugs protect the joints from further destruction.

As TNF is also involved in other chronic inflammatory diseases, their pioneering work has led to anti-TNF therapy being used routinely for Crohn's inflammatory bowel disease, psoriatic arthritis and ankylosing spondylitis as well as for children with chronic arthritis (such as juvenile idiopathic arthritis). The discovery of anti-TNF also spawned a host of other biological therapies for inflammatory arthritis.

Maini and Feldmann have been recognised for this work on previous occasions, having been awarded the Albert Lasker Award for Clinical Medical Research in 2003, and the Crafoord Prize of the Royal Swedish Academy of Science in 2000. Both also received knighthoods in recognition of their achievements.
Professor Sir Ravinder Maini, now visiting professor at the Kennedy Institute of Rheumatology at the University of Oxford, commented: “The discovery that inhibiting just one molecule could make such a huge difference to the many sufferers of this terrible disease was a truly remarkable find. It is extremely pleasing to find our research has benefited so many, and has been recognised through this award.”

Professor Sir Marc Feldmann, now head of the Kennedy Institute, added: “We welcome the presentation of this award, and it is an absolute pleasure to see that well funded long-term research such as that supported by Arthritis Research UK can have such benefit for patients on a global scale. The strength of our research that we were able to develop enabled us to influence the pharmaceutical industry to take a bold step and move into new territory, which proved to be very fruitful for those suffering with rheumatoid arthritis".

Similar stories

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Womens Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.

NDORMS academics named NIHR Senior Investigators

Main

Congratulations to Professor Jonathan Rees who has been announced as a National Institute of Health Research (NIHR Senior Investigator).

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.